VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Impact of dendritic cell fusion vaccine on the microenvironment and outcomes in multiple myeloma

David Avigan, MD, Harvard Medical School, Boston, MA, comments on the impact of treatment with a dendritic cell fusion vaccine following autologous transplantation in comparison to autologous transplantation followed by lenalidomide maintenance in patients with multiple myeloma, and discusses how these vaccines may impact T-cell response and clinical outcomes. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter